Loading...
Bilateral Trade Intelligence · $51.1M Total Trade · 227 Foreign Suppliers · 166 Indian Buyers · DGFT Verified · Updated March 2026
India imported $51.1M worth of pharmaceutical formulations from Canada across 3,250 verified shipments, from 227 foreign suppliers to 166 Indian buyers. The top suppliers are TEVA CANADA LIMITED ($18.7M) and APOTEX INC ($4.2M). The leading products are Simvastatin ($8.8M) and Lactulose ($6.5M). Average shipment value: $15.7K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Simvastatin | $8.8M | 17.3% |
| 2 | Lactulose | $6.5M | 12.7% |
| 3 | Citalopram | $5.3M | 10.3% |
| 4 | Escitalopram | $5.3M | 10.3% |
| 5 | Fluticasone | $4.0M | 7.7% |
| 6 | Omeprazole | $3.4M | 6.6% |
| 7 | Tofacitinib | $3.1M | 6.0% |
| 8 | Atorvastatin | $2.5M | 4.9% |
| 9 | Paclitaxel | $1.5M | 2.9% |
| 10 | Metformin | $1.2M | 2.3% |
| 11 | Dolutegravir | $1.0M | 2.0% |
| 12 | Tenofovir | $910.5K | 1.8% |
| 13 | Lisinopril | $801.3K | 1.6% |
| 14 | Serum | $777.5K | 1.5% |
| 15 | Vaccine | $674.4K | 1.3% |
India imports 20+ pharmaceutical formulations from Canada with a combined trade value of $51.1M. Key products include Simvastatin ($8.8M), Lactulose ($6.5M), Citalopram ($5.3M), Escitalopram ($5.3M), Fluticasone ($4.0M). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 3,250 verified Indian Customs (DGFT) shipment records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Canada and India has experienced significant growth over the past decade. In 2024, India imported pharmaceutical products valued at $37.54 million from Canada, marking a substantial increase from previous years. This upward trend reflects the strengthening of bilateral trade relations and India's growing demand for high-quality pharmaceutical formulations. The collaboration between Canadian suppliers and Indian buyers has been pivotal in this expansion, with 227 Canadian suppliers and 166 Indian buyers facilitating 3,250 shipments valued at an average of $16,000 each.
Canada's contribution to India's pharmaceutical imports is noteworthy, with a total import value of $51.1 million over the past five years. This positions Canada as a significant player in India's pharmaceutical supply chain. The top ten imported products from Canada include Simvastatin, Lactulose, Citalopram, Escitalopram, Fluticasone, Omeprazole, Tofacitinib, Atorvastatin, Paclitaxel, and Metformin, indicating a diverse range of therapeutic areas addressed by Canadian exports.
These are the top pharmaceutical products exported from India to Canada, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Canada buyers, regulatory requirements, and logistics for that specific product corridor. Products include Simvastatin ($8.8M), Lactulose ($6.5M), Citalopram ($5.3M), Escitalopram ($5.3M), Fluticasone ($4.0M) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
227 Indian pharmaceutical companies export finished formulations to Canada. Leading exporters include Teva Canada Limited, Apotex Inc, Abbott Products Operations Ag, Pharmascience Inc. The top exporter accounts for 36.5% of total India–Canada pharma exports. Source: Indian Customs (DGFT).
166 companies in Canada import pharmaceutical formulations from India. Top buyers include Actavis Pharma Development Centre Private Limited, Apotex Research Private Limited, Arshiya Logistics Services Limited, Granules India Limited. The largest buyer accounts for 36.6% of India–Canada pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, several key developments have influenced the pharmaceutical trade between Canada and India. The Central Drugs Standard Control Organisation (CDSCO) has implemented policy changes to streamline the registration process for foreign pharmaceutical products, enhancing the ease of market entry for Canadian companies. Additionally, trade agreements and regulatory harmonization efforts have been initiated to bolster bilateral trade, focusing on mutual recognition of manufacturing standards and expedited customs procedures.
Registration process, GMP requirements, import documentation
Canadian pharmaceutical companies seeking to import products into India must navigate the CDSCO registration process, which involves several critical steps. Initially, companies must register their manufacturing sites with CDSCO, a prerequisite for product registration. This process includes submitting an application with detailed information about the manufacturing facility, such as its address, contact details, and a copy of the manufacturing license. The registration is typically valid for five years, after which renewal is required. Once the manufacturing site is registered, companies can proceed to register individual products by submitting Form 40 or 41, depending on the product category. The registration process may be expedited if the product has been approved by recognized regulatory authorities, potentially waiving the need for local clinical trials. The overall timeline for product registration can vary, but it generally takes several months to complete.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practices (GMP) standards as outlined by the World Health Organization (WHO). Manufacturers must provide evidence of compliance with these standards, which may include certificates from recognized authorities. CDSCO conducts inspections to verify adherence to GMP, ensuring that imported pharmaceutical products meet India's quality and safety requirements. Manufacturers are also encouraged to obtain WHO prequalification for their products, as this can facilitate smoother market entry and acceptance within India.
To import pharmaceutical products into India, Canadian companies must prepare and submit several key documents. These include an import license (Form 10), a registration certificate from CDSCO, a No Objection Certificate (NOC) from the manufacturer, a test license, and compliance with customs procedures. The import license is essential for the legal entry of pharmaceutical products into India, while the registration certificate confirms that the products have been approved by CDSCO. The NOC and test license are required to ensure that the products meet Indian standards and regulations. Adherence to customs procedures is crucial to facilitate the smooth clearance of goods through Indian ports.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Canada are predominantly in the form of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The top ten imported products encompass a range of therapeutic areas, with Simvastatin leading at $8.8 million, followed by Lactulose at $6.5 million, and Citalopram and Escitalopram each at $5.3 million. This diversity indicates that Canadian pharmaceutical exports to India address various medical needs, from cardiovascular to psychiatric conditions.
Canadian pharmaceutical companies export a variety of innovative and specialty products to India, including patented drugs, biologics, and novel formulations not manufactured domestically. These products often fill critical gaps in India's healthcare system, providing patients with access to advanced therapies. The importation of such products is facilitated by India's recognition of the quality and efficacy of Canadian pharmaceuticals, as well as the regulatory approvals granted by CDSCO.
India's demand for pharmaceutical imports from Canada is driven by several factors. The protection of intellectual property rights in Canada ensures that patented drugs are available for import, meeting the needs of patients requiring specific therapies. Additionally, Canada's advanced pharmaceutical manufacturing technologies and adherence to international quality standards address technology gaps in India. The high disease burden in India, coupled with the need for quality medications, further drives the importation of Canadian pharmaceutical products.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes a Most Favored Nation (MFN) tariff rate, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The MFN tariff rate is applied to imports from countries with which India has trade agreements, while the basic customs duty is a standard tax imposed on imported goods. The IGST is applicable to all goods and services imported into India, and the health cess is a specific tax levied on certain goods, including pharmaceuticals, to fund health initiatives. These tariffs collectively impact the final cost of imported pharmaceutical products in India.
India and Canada have engaged in trade negotiations to enhance bilateral relations, focusing on mutual recognition of manufacturing standards and regulatory processes. While there is no comprehensive Free Trade Agreement (FTA) between the two countries, ongoing discussions aim to establish preferential duty rates and streamline customs procedures. These efforts are intended to facilitate smoother trade flows and encourage increased pharmaceutical imports from Canada to India.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, plays a significant role in the pharmaceutical import landscape. This section restricts the patenting of new forms of known substances unless they demonstrate enhanced efficacy. While this provision aims to prevent evergreening of patents, it can impact the availability of certain imported patented drugs. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. This price control mechanism can influence the demand for imported pharmaceutical products from Canada.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Canada to India primarily utilize sea and air routes. Major sea routes involve transshipment through ports in Europe or the Middle East, with transit times ranging from 20 to 30 days, depending on the specific ports and shipping schedules. Air shipments are expedited, typically taking 5 to 7 days, and are often preferred for high-value or time-sensitive products. The reliability of these routes is generally high, with established shipping lines and air cargo services ensuring consistent delivery schedules.
In Canada, pharmaceutical exports are primarily handled through major ports such as the Port of Vancouver and the Port of Montreal, which are equipped with facilities to manage pharmaceutical shipments. In India, key import ports include the Jawaharlal Nehru Port in Mumbai and the Chennai Port, both of which have dedicated facilities for handling pharmaceutical products. These ports are equipped with the necessary infrastructure to ensure the safe and efficient handling of pharmaceutical imports.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance procedures, which include verification of import documentation, inspection of goods, and compliance with CDSCO regulations. CDSCO conducts testing to ensure that imported pharmaceutical products meet Indian quality standards. For temperature-sensitive products, maintaining the cold chain is critical. Indian customs authorities and logistics providers are equipped to handle cold chain requirements, ensuring that products are stored and transported at appropriate temperatures throughout the import process.
Market size, healthcare system, growth outlook
Despite being a major manufacturer of generic pharmaceuticals, India imports a significant portion of its pharmaceutical products, particularly patented drugs, biologics, and novel formulations not produced domestically. This dependency is driven by the need to access advanced therapies and address specific medical conditions that require specialized treatments. Canada's pharmaceutical exports play a crucial role in meeting these needs, providing high-quality products that complement India's domestic manufacturing capabilities.
Major Canadian pharmaceutical companies, such as Apotex, have established a presence in India through direct exports and partnerships with local firms. These companies employ strategies like contract manufacturing and joint ventures to navigate the Indian market effectively. By collaborating with Indian partners, Canadian firms can leverage local market knowledge and distribution networks, enhancing their reach and competitiveness in the Indian pharmaceutical sector.
India exported pharmaceuticals worth $51.1M to Canada across 3,250 verified shipments.
1. TEVA CANADA LIMITED — $18.7M. 2. APOTEX INC — $4.2M. 3. ABBOTT PRODUCTS OPERATIONS AG — $2.5M. Total: 227 suppliers.
1. ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED — $18.7M. 2. APOTEX RESEARCH PRIVATE LIMITED — $4.3M. 3. Arshiya Logistics Services LIMITED — $1.5M. 166 buyers total.
1. Simvastatin ($8.8M, 17.3%); 2. Lactulose ($6.5M, 12.7%); 3. Citalopram ($5.3M, 10.3%); 4. Escitalopram ($5.3M, 10.3%); 5. Fluticasone ($4.0M, 7.7%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $51.1M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$15.7K per consignment across 3,250 shipments.
227 Indian companies. Largest: TEVA CANADA LIMITED with $18.7M.
TransData Nexus covers 227 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 3,250 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
227 Exporters
166 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists